Regulatory Intelligence · Analysis · Advocacy
Iota Intel helps organizations understand, shape, and respond to consequential regulation and public policy. We combine statutory and regulatory research, operational analysis, evidence development, and cross-border business insight to produce persuasive public submissions, executive decision support, implementation roadmaps, and regulated-market entry strategy.
Two core areas, one discipline — the close reading of authority, evidence, and consequence — plus selective work where complex problems cross regulatory, operational, and commercial lines.
While a rule is still proposed, we analyze what it does and what it would cost you, help you decide whether to support, modify, or oppose, and draft the sourced comment letter that puts your position on the record — built as a template your members can file under their own name. Once a rule is final, we deliver a compliance teardown — what you must do and avoid, by when — and an initial legal-vulnerability review of whether the agency met its obligations under the APA. That review is research to start the conversation with counsel, not a substitute for it. The same discipline applies to sub-regulatory guidance — the FAQs, bulletins, and interpretive documents that bind in practice even without notice-and-comment; we help you read those too.
The regulatory approach and justification to bring a product or service into a new market — pathway and stakeholder mapping, market-access analysis, and the procurement, reimbursement, approval, and institutional-adoption considerations that actually gate entry, along with the partner or local-capability requirements involved. Includes GCC and other regulated international-market assessments. For in-country submissions we team with local specialists; we bring the strategy and the regulatory reasoning.
Beyond regulatory matters, we selectively take on a limited number of complex engagements — founders, boards, and institutions facing decisions that cross regulatory, operational, and commercial lines, where senior, interdisciplinary judgment is scarce.
Five questions we ask of every proposed or final rule. The discipline is the product.
What does the statute actually permit — and where are its limits?
What does the record support, and where is it thin or unexamined?
How does this land in real operations, for real organizations and people?
Who is affected, and what follows that the agency may not have weighed?
What workable option better fits the authority and the evidence?
We don't read regulation only at the abstract legal level. We examine how it affects the organizations, systems, workers, patients, consumers, and investors who actually live with it — which is where most analysis stops short, and where the decisive issues usually are.
Concrete, defined work products — not open-ended retainers.
A close legal read of a proposed pesticide-tolerance rule — tested against the FFDCA "reasonable certainty of no harm" standard, the agency's duty to respond to significant comments, and the narrowed deference landscape after Loper Bright and Relentless.
An implementation analysis of a rule executing a specific statutory mandate (MoCRA § 3505) — mapping the testing methodology, phase-in, small-business compliance path, and where the agency's record is strongest.
A constructive, build-it-this-way response to an RFI: a workable definition, a tiered disclosure approach, and integration with existing federal data systems — the kind of input an agency can actually operationalize.
Where burden can be cut and where it can't — principles and targeted recommendations balancing compliance cost against measurable risk, with attention to small manufacturers and import certification.
A fully sourced comment on the agency's draft CCL 6 — a 34-footnote evidentiary framework, framed for durability in the post–Loper Bright environment.
A comment grounded in global FHIR-adoption evidence and a voluntary industry pledge — pairing U.S. rulemaking with international benchmarking. Filed by founder Bradley Shogren under an Iota Intel affiliation.
Each is part of the public record; full letters are available on request. Every letter is written to be transferable — a model a client can adapt and file under their own name or letterhead.
From organizations without a dedicated policy team to in-house teams that need senior surge capacity during heavy comment periods — or arms-length drafting when a position is better advanced through a coalition or filed under another name. In every case: focused senior attention, interdisciplinary depth, and the flexibility to move quickly.
Who's behind Iota Intel
Iota Intel is led by Bradley Shogren. He spent more than 15 years in regulatory affairs and compliance at one of the nation's largest health enterprises, through the director level — leading a regulatory team at Optum that kept policies compliant across the healthcare and prescription-drug delivery chain, for a variety of programs and multiple payer types. He translated federal and state requirements into enterprise operations across a complex, regulated business. That sits on top of an earlier career in international business and cross-border trade, and active interest in the GCC. A former firefighter, he brings a frontline sense of how rules meet reality. The range is the point: the method that reads a drinking-water rule reads a device-market pathway or a benefits-compliance question just as well. More about Bradley →
The first step toward solving a complex challenge begins with a conversation.